{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:31:35Z","timestamp":1777303895434,"version":"3.51.4"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["PTDC\/MED-FAR\/31136\/2017"],"award-info":[{"award-number":["PTDC\/MED-FAR\/31136\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UID\/04138\/2025"],"award-info":[{"award-number":["UID\/04138\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Free Radical Biology and Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.freeradbiomed.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:58:17Z","timestamp":1773676697000},"page":"563-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The interplay between the thioredoxin system and hypoxia-related factors in cancer"],"prefix":"10.1016","volume":"249","author":[{"given":"Isabella","family":"Bramatti","sequence":"first","affiliation":[]},{"given":"Vasco","family":"Branco","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-7910","authenticated-orcid":false,"given":"Cristina","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib1","series-title":"Global Cancer Observatory","year":"2022"},{"issue":"13","key":"10.1016\/j.freeradbiomed.2026.03.040_bib2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/ars.2017.7485","article-title":"Redox paradox: a novel approach to therapeutics-resistant cancer","volume":"29","author":"Chaiswing","year":"2018","journal-title":"Antioxidants Redox Signal."},{"issue":"24","key":"10.1016\/j.freeradbiomed.2026.03.040_bib3","doi-asserted-by":"crossref","first-page":"13963","DOI":"10.1016\/S0021-9258(18)71625-6","article-title":"Thioredoxin and glutaredoxin systems","volume":"264","author":"Holmgren","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.freeradbiomed.2026.03.040_bib4","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1073\/pnas.100114897","article-title":"Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol\/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence","volume":"97","author":"Zhong","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib7","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10059-013-0121-y","article-title":"Regulation of HIF-1\u03b1 activity by overexpression of thioredoxin is independent of thioredoxin reductase status","volume":"36","author":"Naranjo-Suarez","year":"2013","journal-title":"Mol. Cells"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01292-6","article-title":"Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI67230","article-title":"Review series HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbcan.2013.12.005","article-title":"Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"40","key":"10.1016\/j.freeradbiomed.2026.03.040_bib13","doi-asserted-by":"crossref","first-page":"69139","DOI":"10.18632\/oncotarget.19932","article-title":"The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib14","first-page":"1","article-title":"Hypoxia signaling in human health and diseases: implications and prospects for therapeutics","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib15","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.2147\/OTT.S259016","article-title":"Resveratrol suppresses tumor progression via inhibiting Stat3\/Hif-1\u03b1\/Vegf pathway in an orthotopic rat model of non-small-cell lung cancer (Nsclc)","volume":"13","author":"Wang","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax7945","article-title":"Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death","volume":"6","author":"Busker","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101646","article-title":"To inhibit TrxR1 is to inactivate STAT3\u2013Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors","volume":"36","author":"Busker","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-Mediated: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862743","article-title":"The relationship of redox with hallmarks of cancer: the importance of homeostasis and context","volume":"12","author":"Xing","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive oxygen species: drivers of physiological and pathological processes","volume":"13","author":"Checa","year":"2020","journal-title":"J. Inflamm. Res."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in cancer","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib23","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci."},{"issue":"13","key":"10.1016\/j.freeradbiomed.2026.03.040_bib24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/ars.2016.6925","article-title":"Redox signaling mediated by thioredoxin and glutathione systems in the central nervous system","volume":"27","author":"Ren","year":"2017","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.redox.2017.05.024","article-title":"Impaired cross-talk between the thioredoxin and glutathione systems is related to ASK-1 mediated apoptosis in neuronal cells exposed to mercury","volume":"13","author":"Branco","year":"2017","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib26","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2007.9.25","article-title":"Thioredoxin and related molecules-from biology to health and disease","volume":"9","author":"Lillig","year":"2007","journal-title":"Antioxidants Redox Signal."},{"issue":"30","key":"10.1016\/j.freeradbiomed.2026.03.040_bib27","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.0701549104","article-title":"Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide","volume":"104","author":"Lu","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib28","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.2174\/0929867326666190201113004","article-title":"Thioredoxin, glutathione and related molecules in tumour of the nervous system","volume":"27","author":"Branco","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib29","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.3390\/antiox11122345","article-title":"Nrf2 and oxidative stress: a general overview of mechanisms and implications in human disease","volume":"11","author":"Ngo","year":"2022","journal-title":"Antioxidants"},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/antiox13101211","article-title":"NRF2 and thioredoxin reductase 1 as modulators of interactions between zinc and selenium","volume":"13","author":"L\u00f6ser","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of Nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib32","first-page":"109","article-title":"Current approaches and emerging directions in HER2-Resistant breast cancer","volume":"8","author":"Brufsky","year":"2014","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02660-5","article-title":"The molecular biology and therapeutic potential of Nrf2 in leukemia","volume":"22","author":"Khodakarami","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.freeradbiomed.2026.03.040_bib34","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1007\/s12035-015-9506-6","article-title":"NRF2 mediates neuroblastoma proliferation and resistance to retinoic acid cytotoxicity in a model of in vitro neuronal differentiation","volume":"53","author":"de Miranda Ramos","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.freeradbiomed.2026.03.040_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081879","article-title":"Role of NRF2 in lung cancer","volume":"10","author":"S\u00e1nchez-Ortega","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/antiox8100471","article-title":"Redox-mediated mechanism of chemoresistance in cancer cells","volume":"8","author":"Kim","year":"2019","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the hallmarks of cancer","volume":"34","author":"Rojo de la Vega","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/792639","article-title":"Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?","volume":"2011","author":"Son","year":"2011","journal-title":"J Signal Transduct"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112142","article-title":"Reactive Oxygen Species (ROS) in cancer pathogenesis and therapy: an update on the role of ROS in anticancer action of benzophenanthridine alkaloids","volume":"143","author":"Khan","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/antiox13020199","article-title":"Redox regulation of PTEN by reactive oxygen species: its role in physiological processes","volume":"13","author":"Trinh","year":"2024","journal-title":"Antioxidants"},{"issue":"2\u20133","key":"10.1016\/j.freeradbiomed.2026.03.040_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0014-5793(03)00517-9","article-title":"PI3K is a key molecule in the Nrf2-Mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells","volume":"546","author":"Nakaso","year":"2003","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2014.07.017","article-title":"Targeting antioxidants for cancer therapy","volume":"92","author":"Glasauer","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib43","article-title":"Molecular mechanisms of ROS-modulated cancer chemoresistance and therapeutic strategies","volume":"165","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41698-023-00362-3","article-title":"Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade","volume":"7","author":"Fox","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib46","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2008.06.082","article-title":"Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer","volume":"135","author":"Shibata","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.freeradbiomed.2026.03.040_bib47","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s12035-020-01928-z","article-title":"Thioredoxin system protein expression is associated with poor clinical outcome in adult and paediatric gliomas and medulloblastomas","volume":"57","author":"Yao","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.bi.54.070185.001321","article-title":"Thioredoxin","volume":"54","author":"Holmgren","year":"1985","journal-title":"Annu. Rev. Biochem."},{"issue":"45","key":"10.1016\/j.freeradbiomed.2026.03.040_bib49","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.1002\/chem.201905792","article-title":"The thioredoxin system: a promising target for cancer drug development","volume":"26","author":"Ghareeb","year":"2020","journal-title":"Chem. Eur J."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0167-4781(94)90242-9","article-title":"Isolation and characterization of a novel CDNA from HL-60 cells treated with 1,25-Dihydroxyvitamin D-3","volume":"1219","author":"Chen","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.freeradbiomed.2026.03.040_bib51","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/antiox11112161","article-title":"The role of the thioredoxin system in brain diseases","volume":"11","author":"Bj\u00f8rklund","year":"2022","journal-title":"Antioxidants"},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102874","article-title":"Thioredoxin confers intrinsic resistance to cytostatic drugs in human glioma cells","volume":"19","author":"Haas","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.freeradbiomed.2026.03.040_bib53","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1089\/ars.2012.4757","article-title":"The thioredoxin system as a therapeutic target in human health and disease","volume":"19","author":"Mahmood","year":"2013","journal-title":"Antioxidants Redox Signal."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib54","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1074\/jbc.M708169200","article-title":"Thioredoxin-Interacting protein (Txnip) is a critical regulator of hepatic glucose production","volume":"283","author":"Chutkow","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib55","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1371\/journal.pmed.0040158","article-title":"TXNIP regulates peripheral glucose metabolism in humans","volume":"4","author":"Parikh","year":"2007","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bbagen.2009.01.014","article-title":"Focus on mammalian thioredoxin Reductases--Important selenoproteins with versatile functions","volume":"1790","author":"Arn\u00e9r","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"428","key":"10.1016\/j.freeradbiomed.2026.03.040_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf7444","article-title":"Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy","volume":"10","author":"Stafford","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib58","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00280-019-03869-4","article-title":"The role of thioredoxin system in cancer: strategy for cancer therapy","volume":"84","author":"Jia","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-022-04155-y","article-title":"Thioredoxin reductase 3 suppression promotes colitis and carcinogenesis via activating pyroptosis and necrosis","volume":"79","author":"Liu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib60","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semcancer.2006.10.009","article-title":"The thioredoxin system in cancer","volume":"16","author":"Arn\u00e9r","year":"2006","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/ars.2022.0074","article-title":"Thioredoxin signaling pathways in cancer","volume":"38","author":"Zhang","year":"2023","journal-title":"Antioxidants Redox Signal."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI200523001","article-title":"Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells","volume":"115","author":"Yamawaki","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib63","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.yexcr.2003.07.005","article-title":"Thioredoxin inhibits microvascular endothelial capillary tubule formation","volume":"291","author":"Farina","year":"2003","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1432-1033.2001.01892.x","article-title":"Thioredoxin alters the matrix metalloproteinase\/tissue inhibitors of metalloproteinase balance and stimulates human SK-N-SH neuroblastoma cell invasion","volume":"268","author":"Farina","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib65","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jcb.20585","article-title":"Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells","volume":"96","author":"Gan","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib66","first-page":"235","article-title":"The thioredoxin redox inhibitors 1-Methylpropyl 2-Imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 and vascular endothelial growth factor formation 1","volume":"2","author":"Welsh","year":"2003","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib67","series-title":"The Redox Protein Thioredoxin-1 (Trx-1) Increases Hypoxia-Inducible Factor 1 Protein Expression: Trx-1 Overexpression Results in Increased Vascular Endothelial Growth Factor Production and Enhanced Tumor Angiogenesis 1","author":"Welsh","year":"2002"},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib68","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1089\/ars.2004.6.858","article-title":"Complex role of heme Oxygenase-1 in angiogenesis","volume":"6","author":"Dulak","year":"2004","journal-title":"Antioxidants Redox Signal."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib69","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/15230860260220067","article-title":"Modulation of the thioredoxin system during inflammatory responses and its effect on heme Oxygenase-1 expression","volume":"4","author":"Ejima","year":"2002","journal-title":"Antioxidants Redox Signal."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib70","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/ars.2015.6580","article-title":"The hallmarks of cancer from a redox perspective","volume":"25","author":"Hornsveld","year":"2016","journal-title":"Antioxidants Redox Signal."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib71","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1172\/JCI137585","article-title":"Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells","volume":"130","author":"Yang","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/antiox7120177","article-title":"Piecing together how peroxiredoxins maintain genomic stability","volume":"7","author":"West","year":"2018","journal-title":"Antioxidants"},{"issue":"24","key":"10.1016\/j.freeradbiomed.2026.03.040_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21249499","article-title":"TXNIP regulates natural killer cell-mediated innate immunity by inhibiting IFN-\u03b3 production during bacterial infection","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib74","article-title":"Linking tumor microenvironment to plasticity of cancer stem cells: mechanisms and application in cancer therapy","volume":"11","author":"Zheng","year":"2021","journal-title":"Front. Oncol."},{"issue":"24","key":"10.1016\/j.freeradbiomed.2026.03.040_bib75","doi-asserted-by":"crossref","first-page":"7143","DOI":"10.1111\/febs.15695","article-title":"Oxygen regulation of TET enzymes","volume":"288","author":"Matuleviciute","year":"2021","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib76","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/biomedicines11051388","article-title":"The influence of gut microbiota on oxidative stress and the immune system","volume":"11","author":"Kunst","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.redox.2016.11.005","article-title":"Redox control of senescence and age-related disease","volume":"11","author":"Chandrasekaran","year":"2017","journal-title":"Redox Biol."},{"issue":"9","key":"10.1016\/j.freeradbiomed.2026.03.040_bib78","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/carcin\/bgs230","article-title":"Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis","volume":"33","author":"Carlson","year":"2012","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib79","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2005.04.028","article-title":"Thioredoxin reductase as a novel molecular target for cancer therapy","volume":"236","author":"Nguyen","year":"2006","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib80","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/carcin\/bgr137","article-title":"Thioredoxin-interacting protein suppresses bladder carcinogenesis","volume":"32","author":"Nishizawa","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.883297","article-title":"The role of the thioredoxin detoxification system in cancer progression and resistance","volume":"9","author":"Jovanovi\u0107","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib82","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.redox.2015.12.004","article-title":"The thioredoxin system in breast cancer cell invasion and migration","volume":"8","author":"Bhatia","year":"2016","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.freeradbiomed.2026.03.040_bib83","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ijc.23709","article-title":"The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants","volume":"123","author":"Ceccarelli","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib84","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/hp.2000.6546","article-title":"Thioredoxin, a putative oncogene Product,Is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival","volume":"31","author":"Grogan","year":"2000","journal-title":"Hum. Pathol."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib85","first-page":"3087","article-title":"Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer","volume":"7","author":"Kakolyris","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib86","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-2143(03)00068-4","article-title":"Increased expression of Thioredoxin-1 in human colorectal cancer is associated with decreased patient survival","volume":"142","author":"Raffel","year":"2003","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.04.036","article-title":"Thioredoxin-1 promotes colorectal cancer invasion and metastasis through crosstalk with S100P","volume":"401","author":"Lin","year":"2017","journal-title":"Cancer Lett."},{"issue":"5\u20136","key":"10.1016\/j.freeradbiomed.2026.03.040_bib88","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0891-5849(99)00101-X","article-title":"Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to Cis-Diamminedichloroplatinum (II)","volume":"27","author":"Sasada","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib89","first-page":"4293","article-title":"Cellular levels of thioredoxin associated with drug sensitivity to Cisplatin, Mitomycin C, doxorubicin, and etoposide","author":"Yokomizo","year":"1995","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.freeradbiomed.2026.03.040_bib90","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1158\/1078-0432.CCR-05-0449","article-title":"High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer","volume":"11","author":"Kim","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib91","doi-asserted-by":"crossref","first-page":"314","DOI":"10.18632\/oncotarget.463","article-title":"Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-Cell lymphoma","volume":"3","author":"Li","year":"2012","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib92","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbadis.2014.12.002","article-title":"Thioredoxin 1 Upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells","volume":"1852","author":"Wang","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lfs.2017.04.008","article-title":"Inhibition of TrxR2 suppressed NSCLC cell proliferation, metabolism and induced cell apoptosis through decreasing antioxidant activity","volume":"178","author":"Bu","year":"2017","journal-title":"Life Sci."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014356","article-title":"MiR-17\u2217 suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mnfr.200700492","article-title":"Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy","volume":"53","author":"Tonissen","year":"2009","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116844","article-title":"Exposure of human glioblastoma cells to thimerosal inhibits the thioredoxin system and decreases tumor growth-related factors","volume":"484","author":"Bramatti","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib97","series-title":"Preferential Elevation of Prx I and Trx Expression in Lung Cancer Cells Following Hypoxia and in Human Lung Cancer Tissues","author":"Kim","year":"2003"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib98","doi-asserted-by":"crossref","DOI":"10.1259\/bjr\/34180435","article-title":"The thioredoxin system: a key target in tumour and endothelial cells","author":"Mukherjee","year":"2008","journal-title":"Br. J. Radiol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001846","article-title":"Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells","volume":"3","author":"Anest\u00e5l","year":"2008","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib100","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/ars.2015.6378","article-title":"TrxR1 as a potent regulator of the Nrf2-Keap1 response system","volume":"23","author":"Cebula","year":"2015","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib101","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pharmtox-052220-102509","article-title":"Thioredoxin reductase inhibition for cancer therapy","volume":"62","author":"Gencheva","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"7","key":"10.1016\/j.freeradbiomed.2026.03.040_bib102","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/biomedicines10071757","article-title":"The thioredoxin system of mammalian cells and its modulators","volume":"10","author":"Hasan","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.freeradbiomed.2026.03.040_bib103","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.tips.2017.06.001","article-title":"Targeting the thioredoxin system for cancer therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib104","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2007.04.003","article-title":"Thioredoxin signaling as a target for cancer therapy","volume":"7","author":"Powis","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"issue":"29","key":"10.1016\/j.freeradbiomed.2026.03.040_bib105","article-title":"Silver clusters of five atoms as highly selective antitumoral agents through irreversible oxidation of thiols","volume":"32","author":"Porto","year":"2022","journal-title":"Adv. Funct. Mater."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib106","article-title":"The activity of therapeutic molecular cluster Ag5 is dependent on oxygen level and HIF-1 mediated signalling","volume":"76","author":"Twigger","year":"2024","journal-title":"Redox Biol."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib107","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1074\/jbc.M110.214833","article-title":"Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism","volume":"286","author":"K\u00f6nig","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.freeradbiomed.2026.03.040_bib108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.bjp.0707342","article-title":"A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines","volume":"151","author":"Mukherjee","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib109","article-title":"A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2019.03.015","article-title":"Repurposing of Auranofin: thioredoxin reductase remains a primary target of the drug","volume":"162","author":"Zhang","year":"2019","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.taap.2012.05.012","article-title":"Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells","volume":"262","author":"Cai","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib112","first-page":"2097","article-title":"Quercetin induces G2 phase arrest and apoptosis with the activation of P53 in an E6 expression-independent manner in HPV-positive human cervical cancer-derived cells","volume":"19","author":"Clemente-Soto","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jcb.21977","article-title":"Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression","volume":"106","author":"Jeong","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"13","key":"10.1016\/j.freeradbiomed.2026.03.040_bib114","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1073\/pnas.122061399","article-title":"Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant","volume":"99","author":"Zhao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13\u201315","key":"10.1016\/j.freeradbiomed.2026.03.040_bib115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1089\/ars.2021.0038","article-title":"Thioredoxin-interacting protein in cancer and diabetes","volume":"36","author":"Masutani","year":"2022","journal-title":"Antioxidants Redox Signal."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib116","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1007\/s12035-022-02808-4","article-title":"Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in brain cancers","volume":"59","author":"Yao","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib117","article-title":"Inhibition of thioredoxin reductase by santamarine conferring anticancer effect in HeLa cells","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib118","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1021\/tx2000152","article-title":"Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes","volume":"24","author":"Liu","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.freeradbiomed.2014.02.016","article-title":"Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells","volume":"70","author":"Duan","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/0008-5472.CAN-16-0987","article-title":"The natural diterpenoid isoforretin a inhibits Thioredoxin-1 and triggers potent ROS-mediated antitumor effects","volume":"77","author":"Sun","year":"2017","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.freeradbiomed.2026.03.040_bib121","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.bmc.2016.05.066","article-title":"Discovery of anti-cancer activity for Benzo[1,2,4]Triazin-7-Ones: very strong correlation to Pleurotin and thioredoxin reductase inhibition","volume":"24","author":"Sweeney","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"18","key":"10.1016\/j.freeradbiomed.2026.03.040_bib122","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1074\/jbc.M710133200","article-title":"Inhibition of the human thioredoxin system: a molecular mechanism of mercury toxicity","volume":"283","author":"Carvalho","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.889971","article-title":"Thioredoxin reductase inhibitors as potential antitumors: Mercury compounds efficacy in Glioma cells","volume":"9","author":"Pires","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4149\/gpb_2016043","article-title":"Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species","volume":"36","author":"Hwang-Bo","year":"2017","journal-title":"Gen. Physiol. Biophys."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib125","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/ja057358l","article-title":"Inhibition of thioredoxin and thioredoxin reductase by 4-Hydroxy-2-Nonenal in vitro and in vivo","volume":"128","author":"Fang","year":"2006","journal-title":"J. Am. Chem. Soc."},{"issue":"3\u20134","key":"10.1016\/j.freeradbiomed.2026.03.040_bib126","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0891-5849(00)00313-0","article-title":"The role of the redox protein thioredoxin in cell growth and cancer","volume":"29","author":"Powis","year":"2000","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.freeradbiomed.2026.03.040_bib127","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1158\/1078-0432.CCR-12-3165","article-title":"Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia","volume":"19","author":"Gojo","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib128","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-Cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib129","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/14756366.2020.1867121","article-title":"Thioredoxin-dependent system. Application of inhibitors","volume":"36","author":"Jastrz\u0105b","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2018.11.007","article-title":"The thioredoxin system as a target for mercury compounds","volume":"1863","author":"Branco","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1035","key":"10.1016\/j.freeradbiomed.2026.03.040_bib131","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours\u2014implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br. J. Radiol."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib132","first-page":"5447","article-title":"A Nuclear Factor Induced by Hypoxia via de Novo Protein Synthesis Binds to the Human Erythropoietin Gene Enhancer at a Site Required for Transcriptional Activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib133","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/cdd.2008.12","article-title":"Biology of HIF-1\u03b1","volume":"15","author":"Weidemann","year":"2008","journal-title":"Cell Death Differ."},{"issue":"24","key":"10.1016\/j.freeradbiomed.2026.03.040_bib134","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib135","doi-asserted-by":"crossref","first-page":"C260","DOI":"10.1152\/ajpcell.00315.2015","article-title":"Hypoxia-inducible factor 3 biology: complexities and emerging themes","volume":"310","author":"Duan","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib136","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/cas.13483","article-title":"Regulatory mechanisms of hypoxia-inducible factor 1 activity: two decades of knowledge","volume":"109","author":"Koyasu","year":"2018","journal-title":"Cancer Sci."},{"issue":"36","key":"10.1016\/j.freeradbiomed.2026.03.040_bib137","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib138","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"issue":"33","key":"10.1016\/j.freeradbiomed.2026.03.040_bib139","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia Inducible Factor-Alpha Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"6733","key":"10.1016\/j.freeradbiomed.2026.03.040_bib140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.freeradbiomed.2026.03.040_bib141","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib142","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4161\/cbt.4.10.2195","article-title":"Targeting Hypoxia and angiogenesis through HIF-1\u03b1 inhibition","volume":"4","author":"Diaz-Gonzalez","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40675-017-0062-7","article-title":"Hypoxia-inducible factors and cancer","volume":"3","author":"Jun","year":"2017","journal-title":"Curr Sleep Med Rep"},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib144","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3892\/or.2016.5309","article-title":"Advances in the targeting of HIF-1\u03b1 and future therapeutic strategies for glioblastoma multiforme (Review)","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.biocel.2004.08.012","article-title":"Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators","volume":"37","author":"D\u00e9ry","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib146","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00626.2010","article-title":"Regulation of HIF-1\u03b1 activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia","volume":"300","author":"He","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib148","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/onc.2009.441","article-title":"Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics","volume":"29","author":"Semenza","year":"2010","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib149","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/emm.2004.32","article-title":"Association of DNA-dependent protein kinase with hypoxia inducible Factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells","volume":"36","author":"Um","year":"2004","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib150","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/carcin\/bgs142","article-title":"HIF1\u03b1 regulated expression of XPA contributes to Cisplatin resistance in lung cancer","volume":"33","author":"Liu","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib151","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/OTT.S158206","article-title":"The role of HIF-1\u03b1 in Chemo-\/Radioresistant tumors","volume":"11","author":"Xia","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib152","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"23","key":"10.1016\/j.freeradbiomed.2026.03.040_bib153","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib154","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21873\/anticanres.11285","article-title":"Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme","volume":"37","author":"Polivka","year":"2017","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.freeradbiomed.2026.03.040_bib156","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1232-7","article-title":"Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database","volume":"68","author":"Taugourdeau-Raymond","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"963","key":"10.1016\/j.freeradbiomed.2026.03.040_bib157","article-title":"Glioblastoma multiforme: an overview of emerging therapeutic targets","volume":"9","author":"Taylor","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib158","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/annonc\/mdy106","article-title":"Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study","volume":"29","author":"Gramatzki","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib159","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1750-3639.2004.tb00080.x","article-title":"Genetic alterations of phosphoinositide 3\u2010kinase subunit genes in human glioblastomas","volume":"14","author":"Mizoguchi","year":"2004","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib160","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to Anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib161","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1215\/S1152851704001115","article-title":"Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and","volume":"7","author":"Kaur","year":"2005","journal-title":"Neuro Oncol."},{"issue":"5164","key":"10.1016\/j.freeradbiomed.2026.03.040_bib162","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib163","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.freeradbiomed.2014.03.011","article-title":"Acute hypoxia produces a superoxide burst in cells","volume":"71","author":"Hernansanz-Agust\u00edn","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib164","article-title":"Oxidative dimerization of PHD2 is responsible for its inactivation and contributes to metabolic reprogramming via HIF-1\u03b1 activation","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0076-6879(07)35022-2","article-title":"Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors","volume":"435","author":"G\u00f6rlach","year":"2007","journal-title":"Methods Enzymol."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib166","first-page":"1616","article-title":"The effect of curcumin on hypoxia in the tumour microenvironment as a regulatory factor in cancer","volume":"19","author":"Zahedi","year":"2023","journal-title":"Arch. Med. Sci."},{"issue":"12","key":"10.1016\/j.freeradbiomed.2026.03.040_bib167","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.freeradbiomed.2010.03.008","article-title":"HIF-1\u03b1 signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-Expressing adenocarcinoma A549 cells","volume":"48","author":"Malec","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"7123","key":"10.1016\/j.freeradbiomed.2026.03.040_bib168","article-title":"Association of NRF2 with HIF-2\u03b1-Induced cancer stem cell phenotypes in chronic hypoxic condition","volume":"60","author":"Hallis","year":"2023","journal-title":"Redox Biol."},{"issue":"6","key":"10.1016\/j.freeradbiomed.2026.03.040_bib169","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/0008-5472.CAN-10-3007","article-title":"NRF2 blockade suppresses Colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1\u03b1","volume":"71","author":"Kim","year":"2011","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib170","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00501.2020","article-title":"Nrf2 mediates hypoxia-inducible HIF1\u03b1 activation in kidney tubular epithelial cells","volume":"320","author":"Potteti","year":"2021","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"11","key":"10.1016\/j.freeradbiomed.2026.03.040_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-2035-x","article-title":"ROS-mediated inactivation of the PI3K\/AKT pathway is involved in the antigastric cancer effects of thioredoxin Reductase-1 inhibitor chaetocin","volume":"10","author":"Wen","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103032","article-title":"Thioredoxin (Trx): a redox target and modulator of cellular senescence and aging-related diseases","volume":"70","author":"Yang","year":"2024","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9440(10)63145-8","article-title":"Up-Regulation of the Redox mediators Thioredoxin and Apurinic\/Apyrimidinic excision (APE)\/Ref-1 in hypoxic Microregions of Invasive Cervical Carcinomas, mapped using multispectral, wide-field fluorescence image analysis","volume":"164","author":"Hedley","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib174","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1074\/jbc.M608289200","article-title":"Thioredoxin 1 and Thioredoxin 2 have opposed regulatory functions on hypoxia-inducible Factor-1\u03b1","volume":"282","author":"Zhou","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib175","series-title":"Redox Regulation and Therapeutic Approaches in Cancer","article-title":"Redox regulation and therapeutic approaches in cancer","author":"Bansal","year":"2023"},{"issue":"11","key":"10.1016\/j.freeradbiomed.2026.03.040_bib176","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/ATVBAHA.110.209643","article-title":"The emerging role of the thioredoxin system in angiogenesis","volume":"30","author":"Dunn","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030470","article-title":"HIF-independent regulation of thioredoxin reductase 1 contributes to the high levels of reactive oxygen species induced by hypoxia","volume":"7","author":"Naranjo-Suarez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib178","article-title":"The interplay between tumor suppressor P53 and hypoxia signaling pathways in cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib179","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1 \u03b1 and HIF2 \u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.freeradbiomed.2026.03.040_bib181","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1873-3468.13525","article-title":"Modeling the regulation of P53 activation by HIF-1 upon hypoxia","volume":"593","author":"Wang","year":"2019","journal-title":"FEBS Lett."},{"issue":"25","key":"10.1016\/j.freeradbiomed.2026.03.040_bib182","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1074\/jbc.M109.008557","article-title":"Reactive oxygen species-independent oxidation of thioredoxin in hypoxia","volume":"284","author":"Muniyappa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113861","article-title":"Targeting hypoxia-inducible Factor-1alpha: a new strategy for triple-negative breast cancer therapy","volume":"156","author":"Liu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib184","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/cancers2020209","article-title":"Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation","volume":"2","author":"Karlenius","year":"2010","journal-title":"Cancers"},{"key":"10.1016\/j.freeradbiomed.2026.03.040_bib185","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211067111","article-title":"Human Papillomavirus16 E6 but not E7 upregulates GLUT1 expression in lung cancer cells by upregulating thioredoxin expression","volume":"20","author":"Gao","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib186","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1074\/jbc.M113.503938","article-title":"Thioredoxin-mediated denitrosylation regulates cytokine-induced nuclear factor \u039aB (NF-\u039aB) activation","volume":"289","author":"Kelleher","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.freeradbiomed.2026.03.040_bib187","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303259","article-title":"Nitric oxide: physiological functions, delivery, and biomedical applications","volume":"10","author":"Andrabi","year":"2023","journal-title":"Adv. Sci."},{"issue":"5","key":"10.1016\/j.freeradbiomed.2026.03.040_bib188","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/antiox9050374","article-title":"The double-faced role of nitric oxide and reactive oxygen species in solid tumors","volume":"9","author":"Mijatovi\u0107","year":"2020","journal-title":"Antioxidants"},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib189","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/0929867033457746","article-title":"The role of Nitric Oxide (NO) in stability regulation of hypoxia inducible Factor-1alpha (HIF-1alpha)","volume":"10","author":"Brune","year":"2003","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.freeradbiomed.2007.09.012","article-title":"The mitochondrial thioredoxin system regulates nitric oxide-induced HIF-1alpha protein","volume":"44","author":"Zhou","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib191","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MPA.0b013e31815929fe","article-title":"Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-Induced gene in pancreatic cancer","volume":"36","author":"Baker","year":"2008","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.freeradbiomed.2026.03.040_bib192","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.freeradbiomed.2010.07.016","article-title":"Thioredoxin-interacting protein inhibits hypoxia-inducible factor transcriptional activity","volume":"49","author":"Farrell","year":"2010","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.freeradbiomed.2026.03.040_bib193","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.celrep.2016.03.029","article-title":"Enhanced transcriptional activity and mitochondrial localization of STAT3 Co-Induce axon regrowth in the adult central nervous system","volume":"15","author":"Luo","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.freeradbiomed.2026.03.040_bib194","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nchembio.1695","article-title":"Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling","volume":"11","author":"Sobotta","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib195","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/1535-7163.MCT-05-0487","article-title":"Molecular pharmacology and antitumor activity of Palmarumycin-based inhibitors of thioredoxin reductase","volume":"5","author":"Powis","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib196","first-page":"1049","article-title":"Antisense-Thioredoxin inhibits angiogenesis via PVHL-mediated hypoxia-inducible Factor-1alpha degradation","volume":"26","author":"Kim","year":"2005","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.freeradbiomed.2026.03.040_bib197","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1096\/fj.202000082R","article-title":"Cross talk between oxidative stress and hypoxia via thioredoxin and HIF-2\u03b1 drives metastasis of hepatocellular carcinoma","volume":"34","author":"Cao","year":"2020","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.freeradbiomed.2026.03.040_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102738","article-title":"Targeting hypoxia-inducible Factor-1\u03b1 for the management of hepatocellular carcinoma","volume":"15","author":"Huynh","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.freeradbiomed.2026.03.040_bib199","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12011-009-8544-1","article-title":"Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302","volume":"136","author":"Li","year":"2010","journal-title":"Biol. Trace Elem. Res."}],"container-title":["Free Radical Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584926002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584926002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:31:31Z","timestamp":1777300291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891584926002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":199,"alternative-id":["S0891584926002315"],"URL":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2026.03.040","relation":{},"ISSN":["0891-5849"],"issn-type":[{"value":"0891-5849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interplay between the thioredoxin system and hypoxia-related factors in cancer","name":"articletitle","label":"Article Title"},{"value":"Free Radical Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}